TransCode Therapeutics RNAZ Stock
TransCode Therapeutics Price Chart
TransCode Therapeutics RNAZ Financial and Trading Overview
| TransCode Therapeutics stock price | 5.04 USD |
| Previous Close | 5.34 USD |
| Open | 5.38 USD |
| Bid | 3.96 USD x 200 |
| Ask | 6.87 USD x 200 |
| Day's Range | 5.25 - 5.75 USD |
| 52 Week Range | 5.01 - 20.99 USD |
| Volume | 10.29K USD |
| Avg. Volume | 9.18K USD |
| Market Cap | 5.16M USD |
| Beta (5Y Monthly) | 1.403 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.71 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
RNAZ Valuation Measures
| Enterprise Value | 129.78M USD |
| Trailing P/E | N/A |
| Forward P/E | -9.058499 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 0.48221987 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -6.789 |
Trading Information
TransCode Therapeutics Stock Price History
| Beta (5Y Monthly) | 1.403 |
| 52-Week Change | -22.63% |
| S&P500 52-Week Change | 27.29% |
| 52 Week High | 20.99 USD |
| 52 Week Low | 5.01 USD |
| 50-Day Moving Average | 7.75 USD |
| 200-Day Moving Average | 9.46 USD |
RNAZ Share Statistics
| Avg. Volume (3 month) | 9.18K USD |
| Avg. Daily Volume (10-Days) | 14.81K USD |
| Shares Outstanding | 950.3K |
| Float | 835.4K |
| Short Ratio | 6.27 |
| % Held by Insiders | 9.22% |
| % Held by Institutions | 8.61% |
| Shares Short | 35.76K |
| Short % of Float | 3.89% |
| Short % of Shares Outstanding | 3.89% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:28 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | December 31, 2025 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -14.13% |
| Return on Equity (ttm) | -46.25% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -19116464 USD |
| Net Income Avi to Common (ttm) | -36271288 USD |
| Diluted EPS (ttm) | -3.71 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 17.81M USD |
| Total Cash Per Share (mrq) | 19.43 USD |
| Total Debt (mrq) | 0 USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 6.291 |
| Book Value Per Share (mrq) | 11.271 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -19516228 USD |
| Levered Free Cash Flow (ttm) | -13534154 USD |
Profile of TransCode Therapeutics
| Country | United States |
| State | MA |
| City | Boston |
| Address | 6 Liberty Square |
| ZIP | 02109 |
| Phone | 857 837 3099 |
| Website | https://www.transcodetherapeutics.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 12 |
TransCode Therapeutics, Inc., a clinical-stage company, develops immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers. The company's therapeutic candidate comprises SEVIPROTIMUT-L for the adjuvant treatment of patients with Stages IIB and IIC melanoma that has completed Phase 2 clinical trial; TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others that has completed Phase 1 clinical trial. Its preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1 and two indication agnostic programs; TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; and TTX-siMYC, an siRNA-based MYC inhibitor. The company is also developing oncolytic virus therapy. TransCode Therapeutics, Inc. has strategic collaboration agreement with The University of Texas M. D. Anderson Cancer Center. The company was incorporated in 2016 and is based in Boston, Massachusetts.
Q&A For TransCode Therapeutics Stock
What is a current RNAZ stock price?
TransCode Therapeutics RNAZ stock price today per share is 5.04 USD.
How to purchase TransCode Therapeutics stock?
You can buy RNAZ shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for TransCode Therapeutics?
The stock symbol or ticker of TransCode Therapeutics is RNAZ.
Which industry does the TransCode Therapeutics company belong to?
The TransCode Therapeutics industry is Biotechnology.
How many shares does TransCode Therapeutics have in circulation?
The max supply of TransCode Therapeutics shares is 950.3K.
What is TransCode Therapeutics Price to Earnings Ratio (PE Ratio)?
TransCode Therapeutics PE Ratio is now.
What was TransCode Therapeutics earnings per share over the trailing 12 months (TTM)?
TransCode Therapeutics EPS is -3.71 USD over the trailing 12 months.
Which sector does the TransCode Therapeutics company belong to?
The TransCode Therapeutics sector is Healthcare.
TransCode Therapeutics RNAZ included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| US Tech Composite IXIC | 26853.98 USD — |
-0.89
|
8.32B USD — | 26769.16 USD — | 27130.88 USD — | — - | 8.32B USD — |
| US Tech Health Care IXHC | 1133.51 USD — |
+1.54
|
— — | 1113.35 USD — | 1133.95 USD — | — - | — — |
- {{ link.label }} {{link}}